JP3816518B2
(ja)
*
|
1994-06-10 |
2006-08-30 |
ジェンベク、インコーポレイティッド |
相補的なアデノウイルスベクター系と細胞系
|
US20030148968A1
(en)
*
|
1995-02-28 |
2003-08-07 |
Hammond H. Kirk |
Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
|
JP3961019B2
(ja)
|
1995-02-28 |
2007-08-15 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
遺伝子転移媒介の血管形成療法
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
CA2222140C
(fr)
|
1995-06-15 |
2010-11-23 |
Introgene B.V. |
Systemes d'empaquetage pour adenovirus recombinant chez l'homme, destine a la therapie genique
|
US20020193580A1
(en)
*
|
1995-12-15 |
2002-12-19 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
US20060088938A1
(en)
*
|
1995-12-15 |
2006-04-27 |
Mitchell Lloyd G |
Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
|
US20030027250A1
(en)
*
|
1995-12-15 |
2003-02-06 |
Mitchell Lloyd G. |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
EP0937150A2
(fr)
*
|
1996-09-25 |
1999-08-25 |
Novartis AG |
Lignees cellulaires d'emballage permettant de faciliter le developpement de vecteurs adenoviraux d'une grande capacite
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
IL131021A0
(en)
*
|
1997-01-29 |
2001-01-28 |
Cornell Res Foundation Inc |
Multiple site delivery of adenoviral vector for the induction of angiogenesis
|
US6348450B1
(en)
*
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
AU764686B2
(en)
|
1998-08-28 |
2003-08-28 |
Duke University |
Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
|
US6303362B1
(en)
|
1998-11-19 |
2001-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adenoviral vector and methods for making and using the same
|
AU4437100A
(en)
*
|
1999-04-23 |
2001-02-13 |
Crucell Holland B.V. |
Means and methods for nucleic acid transfer
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US6793926B1
(en)
|
1999-05-27 |
2004-09-21 |
Genovo, Inc. |
Methods for production of a recombinant adeno-associated virus
|
US6627190B2
(en)
*
|
1999-07-12 |
2003-09-30 |
Saint Louis University |
Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
|
US6613516B1
(en)
*
|
1999-10-30 |
2003-09-02 |
Affymetrix, Inc. |
Preparation of nucleic acid samples
|
US6867022B1
(en)
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
US7653769B2
(en)
*
|
2006-12-14 |
2010-01-26 |
International Business Machines Corporation |
Management of devices connected to infiniband ports
|
US6821775B1
(en)
*
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
US6591543B2
(en)
*
|
2000-04-14 |
2003-07-15 |
Kenneth P. Sabine |
Top water lure with highly active propeller
|
KR101250021B1
(ko)
|
2000-05-26 |
2013-04-03 |
다이닛본 스미토모 세이야꾸 가부시끼가이샤 |
완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터
|
US6579522B1
(en)
|
2000-06-27 |
2003-06-17 |
Genvec, Inc. |
Replication deficient adenoviral TNF vector
|
EP1203819A3
(fr)
|
2000-10-06 |
2002-08-07 |
Transgene S.A. |
Vecteurs anti-inflammatoires
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
US20040126774A1
(en)
*
|
2001-01-08 |
2004-07-01 |
Mitchell Lioyd G. |
Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
|
EP1427816A4
(fr)
|
2001-09-18 |
2004-12-01 |
Clontech Lab Inc |
Procede de producteur dde vecteurs adenoviraux s'appuyant sur une recombinase specifique d'un site
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
US20030087438A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
E1-revertant-free adenoviral composition
|
US20030158112A1
(en)
*
|
2002-02-15 |
2003-08-21 |
Johns Hopkins University School Of Medicine |
Selective induction of apoptosis to treat ocular disease
|
US7399753B2
(en)
*
|
2002-02-25 |
2008-07-15 |
Virxsys Corporation |
Trans-splicing mediated photodynamic therapy
|
CA2485341A1
(fr)
*
|
2002-05-08 |
2004-06-17 |
Intronn, Inc. |
Recours a la technique smart pour rendre des adenovirus capables de replication selective des cellules
|
CA2503247A1
(fr)
*
|
2002-10-23 |
2004-05-06 |
Intronn, Inc. |
Procedes de criblage destines a identifier des molecules de pre-trans-epissage efficaces
|
JP2006516027A
(ja)
*
|
2002-12-02 |
2006-06-15 |
ジェンベク、インコーポレイティッド |
眼関連障害の治療用材料および治療方法
|
US20040166091A1
(en)
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
US20050042217A1
(en)
*
|
2003-03-19 |
2005-02-24 |
Yan Qi |
Specific inhibition of allorejection
|
ES2391975T3
(es)
*
|
2003-07-25 |
2012-12-03 |
Genvec, Inc. |
Vacunas a base de vector adenovírico
|
ES2340038T3
(es)
*
|
2003-11-14 |
2010-05-28 |
Genvec, Inc. |
Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable.
|
BRPI0416920A
(pt)
*
|
2003-11-24 |
2007-01-23 |
Canji Inc |
redução de cicatriz dérmica
|
EP1716165A4
(fr)
*
|
2004-01-23 |
2008-06-18 |
Virxsys Corp |
Expression d'apoliproteine a1 (apoa-1) et variants au moyen de transepissage d'arn induit par complexe d'epissage
|
US8053232B2
(en)
|
2004-01-23 |
2011-11-08 |
Virxsys Corporation |
Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
|
US7968334B2
(en)
*
|
2004-01-23 |
2011-06-28 |
Virxsys Corporation |
Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
|
CA2555412C
(fr)
*
|
2004-02-23 |
2013-06-25 |
Crucell Holland B.V. |
Procedes de purification de virus
|
JP2007528903A
(ja)
*
|
2004-03-12 |
2007-10-18 |
ジェンベク、インコーポレイティッド |
眼における血管漏出を処置するための物質
|
EP2567967A3
(fr)
|
2004-04-12 |
2013-08-21 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Méthode pour utiliser les vecteurs adénovirals à mener une réponse immunitaire
|
EP1778296B1
(fr)
*
|
2004-07-20 |
2012-06-06 |
Isogenis, Inc. |
Inhibition specifique d'auto-immunite et maladies associees a des auto-antigenes
|
US20060094110A1
(en)
*
|
2004-07-30 |
2006-05-04 |
Mcgarrity Gerard J |
Use of spliceosome mediated RNA trans-splicing for immunotherapy
|
US20060134658A1
(en)
*
|
2004-08-09 |
2006-06-22 |
Garcia-Blanco Mariano A |
Use of RNA trans-splicing for generation of interfering RNA molecules
|
CA2589602A1
(fr)
*
|
2004-09-01 |
2006-04-13 |
Genvec, Inc. |
Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo
|
DE102004047492B4
(de)
*
|
2004-09-23 |
2006-07-20 |
Jost-Werke Gmbh & Co. Kg |
Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
|
WO2006083331A2
(fr)
*
|
2004-10-08 |
2006-08-10 |
Intronn, Inc |
Utilisation d'un trans-epissage d'arn pour le transfert genique d'anticorps et la production polypeptidique d'anticorps
|
US7871795B2
(en)
|
2004-10-08 |
2011-01-18 |
Virxsys Corporation |
Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
|
US20060188481A1
(en)
*
|
2005-02-22 |
2006-08-24 |
Saitama Medical School |
Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
|
KR20070120970A
(ko)
|
2005-02-23 |
2007-12-26 |
유에이비 리서치 파운데이션 |
알킬-글리코시드로 증진된 예방접종
|
CA2602944C
(fr)
*
|
2005-04-11 |
2015-08-11 |
Crucell Holland B.V. |
Purification de virus faisant appel a une ultrafiltration
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US8765146B2
(en)
*
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
WO2007059461A2
(fr)
*
|
2005-11-10 |
2007-05-24 |
Genvec, Inc. |
Vaccin contre la fievre aphteuse a base de vecteur adenoviral
|
WO2008086386A2
(fr)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Vaccins antipaludéens à base de vecteur adénoviral
|
EP2132300B1
(fr)
*
|
2007-03-09 |
2011-01-12 |
Vectorlogics, Inc. |
Cellules pour la production de protéines et de vecteurs adénoviraux
|
WO2008134720A2
(fr)
*
|
2007-04-30 |
2008-11-06 |
Medtronic, Inc. |
Séquences d'adn inertes pour conditionnement viral efficace et procédés d'utilisation
|
US20090202492A1
(en)
*
|
2008-01-25 |
2009-08-13 |
University Of South Florida |
Adenovirus vaccine utilizing ikk as adjuvant
|
WO2010033722A2
(fr)
|
2008-09-17 |
2010-03-25 |
Isogenis, Inc. |
Construction de vecteurs de délivrance de gènes basés sur un adénovirus complètement délété et ses utilisations
|
MX2011004292A
(es)
*
|
2008-11-03 |
2011-05-31 |
Crucell Holland Bv |
Metodo para la produccion de vectores adenovirales.
|
BR112012008507B8
(pt)
|
2009-10-15 |
2021-05-25 |
Crucell Holland Bv |
método para purificar partículas de adenovírus a partir de uma suspensão de célula
|
KR101749779B1
(ko)
|
2009-10-15 |
2017-06-21 |
크루셀 홀란드 비.브이. |
아데노바이러스 입자의 정제 방법
|
WO2011047316A1
(fr)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Séquences d'acides nucléiques codant pour des protéines mosaïques extensibles du vih
|
WO2011057254A2
(fr)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccins à base de vecteur adénoviral simien
|
EP2853266B1
(fr)
|
2009-11-09 |
2018-01-31 |
Genvec, Inc. |
Adénovirus simiens et procédés d'utilisation
|
NZ601424A
(en)
|
2010-02-15 |
2014-07-25 |
Crucell Holland Bv |
Method for the production of ad26 adenoviral vectors
|
WO2011116189A1
(fr)
|
2010-03-17 |
2011-09-22 |
Cornell University |
Vaccin adénoviral dissocié contre les drogues toxicomanogènes
|
WO2011119773A1
(fr)
|
2010-03-23 |
2011-09-29 |
Roeth Jeremiah F |
Vecteurs exprimant des protéines thérapeutiques de manière conditionnelle, cellules hôtes comprenant les vecteurs, et utilisations associées
|
WO2012021730A2
(fr)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Vaccin contre le virus syncytial respiratoire (vsr)
|
CA2808556A1
(fr)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Vaccination therapeutique contre la tuberculose active
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
WO2012083297A2
(fr)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Vecteurs adénoviraux avec régions d'hexon modifiées
|
WO2012088041A1
(fr)
|
2010-12-20 |
2012-06-28 |
Genvec, Inc. |
Vaccin contre la dengue à base d'un vecteur adénoviral
|
EP3450568A3
(fr)
|
2011-03-04 |
2019-04-24 |
Intrexon Corporation |
Vecteurs exprimant une protéine de manière conditionnelle
|
WO2012162428A1
(fr)
|
2011-05-23 |
2012-11-29 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Primovaccination-rappel pour infection virale
|
JP6757119B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
|
WO2013052859A2
(fr)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral
|
US9617560B2
(en)
|
2011-10-05 |
2017-04-11 |
Genvec, Inc. |
Simian (gorilla) adenovirus or adenoviral vectors and methods of use
|
US9629906B2
(en)
|
2011-10-05 |
2017-04-25 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
EP2809346A1
(fr)
|
2012-02-02 |
2014-12-10 |
GenVec, Inc. |
Vaccin contre la malaria à base d'un vecteur adénoviral
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
AU2013231423B2
(en)
|
2012-03-12 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
KR102023791B1
(ko)
|
2012-03-22 |
2019-09-23 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2855669B1
(fr)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Vecteurs adénoviraux de sérotype 28 modifiés
|
EP2855511B1
(fr)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Vaccin contre le virus de l'herpes simplex
|
CN110590916A
(zh)
|
2013-04-25 |
2019-12-20 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
JP6679475B2
(ja)
|
2013-06-17 |
2020-04-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化された可溶性融合前rsv fポリペプチド
|
DK3046536T3
(en)
|
2013-09-19 |
2019-03-11 |
Janssen Vaccines & Prevention Bv |
IMPROVED ADENOVIRUS FORMULATIONS
|
EP3189067B1
(fr)
|
2014-09-04 |
2021-05-19 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Protéines de l'enveloppe du vih-1 et leur utilisation
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
PT3215187T
(pt)
|
2014-11-04 |
2018-11-27 |
Janssen Vaccines & Prevention Bv |
Vacinas terapêuticas contra hpv16
|
US10420834B2
(en)
|
2014-12-24 |
2019-09-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant metapneumovirus F proteins and their use
|
US10654898B2
(en)
|
2015-01-20 |
2020-05-19 |
The United States of America, as represented by the Secretary, Department of Health and Human Serices |
Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
AU2016232050B2
(en)
|
2015-03-18 |
2022-04-07 |
Janssen Vaccines & Prevention B.V. |
Assays for recombinant expression systems
|
SI3283634T1
(sl)
|
2015-04-14 |
2019-08-30 |
Janssen Vaccines & Prevention B.V. |
Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem
|
WO2017005848A1
(fr)
|
2015-07-07 |
2017-01-12 |
Janssen Vaccines & Prevention B.V. |
Polypeptides f du vrs de pré-fusion solubles stabilisés
|
EP3319633B1
(fr)
|
2015-07-07 |
2020-11-11 |
Janssen Vaccines & Prevention B.V. |
Vaccin contre le vrs
|
BR112018003019A2
(pt)
|
2015-08-20 |
2018-09-25 |
Janssen Vaccines & Prevention Bv |
vacinas terapêuticas contra hpv18
|
WO2017060329A1
(fr)
|
2015-10-06 |
2017-04-13 |
Janssen Vaccines & Prevention B.V. |
Procédés pour la prévention de la dégradation induite par du plastique de produits biologiques
|
WO2017139392A1
(fr)
|
2016-02-08 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protéines d'enveloppe du vih-1 recombinantes et leur utilisation
|
EP3426291A1
(fr)
|
2016-03-09 |
2019-01-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Protéines d'enveloppe recombinées du vih-1 et leur utilisation
|
EA201892250A1
(ru)
|
2016-04-05 |
2019-03-29 |
Янссен Вэксинс Энд Превеншн Б.В. |
Вакцина против rsv
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
SG11201808809PA
(en)
|
2016-05-02 |
2018-11-29 |
Janssen Vaccine & Prevention B V |
Therapeutic hpv vaccine combinations
|
PL3464331T3
(pl)
|
2016-05-30 |
2021-04-19 |
Janssen Vaccines & Prevention B.V. |
Stabilizowane przedfuzyjne białka F RSV
|
JP6683847B2
(ja)
|
2016-06-20 |
2020-04-22 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
強力でバランスのとれた双方向性プロモーター
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
CA3038968A1
(fr)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovecteurs pour l'administration d'un materiel genetique therapeutique dans des lymphocytes t
|
EP3518968B1
(fr)
|
2016-10-03 |
2022-01-05 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Immunogènes de peptides de fusion env du vih-1 et leur utilisation
|
US10960070B2
(en)
|
2016-10-25 |
2021-03-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Prefusion coronavirus spike proteins and their use
|
US11084850B2
(en)
|
2016-12-16 |
2021-08-10 |
The Pirbright Institute |
Recombinant prefusion RSV F proteins and uses thereof
|
WO2018146205A1
(fr)
|
2017-02-09 |
2018-08-16 |
Janssen Vaccines & Prevention B.V. |
Promoteur puissant et court pour l'expression de gènes hétérologues
|
EP3600405A1
(fr)
|
2017-03-24 |
2020-02-05 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Domaines externes modifiés masqués par le glycane du vih-1, gp120, et leur utilisation
|
CA3061278A1
(fr)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Procedes et compositions pour induire une immunite protectrice contre l'infection par le vrs
|
SG11202001458SA
(en)
|
2017-09-15 |
2020-03-30 |
Janssen Vaccines & Prevention Bv |
Method for the safe induction of immunity against rsv
|
WO2019079337A1
(fr)
|
2017-10-16 |
2019-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Protéines d'enveloppe recombinées du vih-1 et leur utilisation
|
WO2019086456A1
(fr)
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adénovirus et utilisations associées
|
AU2018360253B2
(en)
|
2017-10-31 |
2023-11-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
BR112020007698A2
(pt)
|
2017-10-31 |
2020-10-06 |
Janssen Vaccines & Prevention B.V. |
Sequência de ácido nucleico isolada, vetor, seu método de produção, célularecombinante, composição imunogênica, método para induzir uma resposta imune em um indivíduo, vacina e seu método de produção
|
JP7229239B2
(ja)
|
2017-10-31 |
2023-02-27 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクター及びその用途
|
BR112020014343A2
(pt)
|
2018-01-23 |
2020-12-08 |
Janssen Vaccines & Prevention B.V. |
Vacinas contra o vírus da influenza e seus usos
|
EP3762010A4
(fr)
|
2018-03-06 |
2022-04-06 |
Precigen, Inc. |
Vaccins contre l'hépatite b et utilisations de ces derniers
|
CA3117390A1
(fr)
|
2018-10-22 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Proteine gp120 de recombinaison a deletion de la boucle v1
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
US20220204567A1
(en)
|
2019-04-25 |
2022-06-30 |
Janssen Vaccines & Prevention B.V. |
Recombinant influenza antigens
|
US20220273787A1
(en)
|
2019-05-15 |
2022-09-01 |
Janssen Vaccines & Prevention B.V. |
Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
|
JP2022532742A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベースのワクチンによる呼吸器合胞体ウイルス感染の予防的処置
|
CA3140019A1
(fr)
*
|
2019-05-30 |
2020-12-03 |
Gritstone Bio, Inc. |
Adenovirus modifies
|
AU2020342463A1
(en)
|
2019-09-05 |
2022-03-24 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
CA3156471A1
(fr)
|
2019-10-03 |
2021-04-08 |
Janssen Vaccines & Prevention B.V. |
Vecteurs d'adenovirus et leurs utilisations
|
US20220403438A1
(en)
|
2019-10-08 |
2022-12-22 |
Trustees Of Boston College |
Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins
|
EP4061405A1
(fr)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccins basés sur les mutants du gène calr et de la protéine jak2 et leurs utilisations
|
WO2021163365A1
(fr)
|
2020-02-11 |
2021-08-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccin contre le sars-cov-2
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
MX2022010936A
(es)
|
2020-03-05 |
2022-11-16 |
Neotx Therapeutics Ltd |
³métodos y composiciones para el tratamiento del cáncer con células inmunológicas.
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
US11773391B2
(en)
|
2020-04-01 |
2023-10-03 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Therapeutic and diagnostic target for SARS-CoV-2 and COVID-19
|
EP4135757A1
(fr)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Vaccins à base de psma et de steap1 et leurs utilisations
|
CN116096407A
(zh)
|
2020-04-29 |
2023-05-09 |
美国政府(由卫生和人类服务部的部长所代表) |
重组人偏肺病毒f蛋白及其用途
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
US20230029453A1
(en)
|
2020-07-06 |
2023-02-02 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
WO2022009051A1
(fr)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Procédé de détermination de la réactivité à un traitement du cancer de la prostate
|
WO2022035860A2
(fr)
|
2020-08-10 |
2022-02-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vaccins à adénovirus de type 4 aptes à la réplication exprimant des protéines d'enveloppe du vih et leur utilisation
|
US20240228549A1
(en)
|
2021-04-29 |
2024-07-11 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Prefusion-stabilized lassa virus glycoprotein complex and its use
|
AU2022323509A1
(en)
|
2021-08-03 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
|
WO2023091696A1
(fr)
|
2021-11-19 |
2023-05-25 |
Christiana Care Gene Editing Institute, Inc. |
Système d'administration d'adénovirus pour le traitement du cancer
|
WO2023192835A1
(fr)
|
2022-03-27 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation
|
WO2023196898A1
(fr)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptides mimétiques de la bêta globine et leur utilisation
|
EP4338727A1
(fr)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Formulations d'adénovirus
|